DOI: 10.1055/s-00000094

Zeitschrift für Gastroenterologie

References

Lenz HJ, Innocenti F. et al.
CALGB/SWOG 80405: phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with expanded RAS analyses untreated metastatic adenocarcinoma of the colon or rectum (mCRC).
Ann Oncol 2014
25. Suppl 05

Download Bibliographical Data

Search in: